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ZACHARY T. BLOOMGARDEN, MD
T
his is the third of six articles based
on presentations at the American
Diabetes Association Scientiﬁc Ses-
sions held 6–10 June 2008 in San Fran-
cisco, California.
Type 2 diabetes treatment
approaches
Ralph DeFronzo (San Antonio, TX) sug-
gested an interesting set of approaches to
the treatment of type 2 diabetes. De-
Fronzo noted that the natural history of
type 2 diabetes involves a reduction in
insulin sensitivity during the progression
from lean to obese with normal tolerance,
and that the subsequent progression to
impaired glucose tolerance (IGT) is asso-
ciated with a further decrease in insulin
sensitivity and a relative deﬁciency in insu-
lin secretory function. As IGT progresses to
diabetes, insulin secretion decreases
without a further worsening in insulin
sensitivity.DeFronzopresentedstudiesof
normal glucose-tolerant, impaired glu-
cose-tolerant,andtype2diabeticindivid-
uals that demonstrated an increase in the
absolute rate of glucose-induced insulin
secretion during the progression from
normal to varying degrees of IGT, with
insulinsecretionsubsequentlydecreasing
progressively with worsening degrees of
diabetes. Examining the ratio of insulin
secretion to insulin resistance (the dispo-
sition index), DeFronzo showed that the
logarithm of insulin secretion/insulin re-
sistance is inversely proportional to the
log of the 2-h glucose, and that with ad-
vanced degrees of IGT, 80% of insulin
secretory capacity is lost, implying that
insulin deﬁciency begins well before the
onset of diabetes as currently deﬁned. He
cited an autopsy study showing that by
the time elevations occur in fasting glu-
cose, there is a 50% loss of -cell mass,
with a further decrease in -cell volume
with progression to diabetes (1).
The Diabetes Prevention Program
further raises concern about the clinical
implicationsoftheterm“pre-diabetes,”as
the program found a 7.9% prevalence of
diabetic retinopathy among individuals
with IGT. At the time of diabetes diagno-
sis, 12.6% had retinopathy, although the
mean A1C was only 6.1%. Peripheral
neuropathy also was seen in 5–10% of
participants with IGT. DeFronzo con-
cluded that individuals with IGT are near
maximally insulin resistant, with de-
creased -cell function and mass, and
with appreciable prevalence of diabetic
complications.
-cell failure occurs, DeFronzo said,
in an age-related fashion and clusters in
families. The transcription factor 7–like 2
gene(TCF7L2)polymorphismisassociated
with reduced insulin secretion, perhaps
fromreducedinsulinresponsivenesstoglu-
cagon-like peptide (GLP)-1. Carriers of the
abnormal gene have a 60% increase in dia-
betes development. Deﬁciency of GLP-1
and resistance to glucose-dependent insuli-
notropic peptide (GIP) action also occur in
type2diabetes.Lipotoxicityfromincreased
plasma free fatty acids (FFAs) is another
factor impairing insulin secretion. A 48-h
infusion of heparin with triglyceride
emulsion elevating FFAs in normal glu-
cose tolerant offspring of two diabetic
parentsledtodecreasedinsulinsecretion.
Increased glucose levels also impair insu-
lin secretion, the phenomenon of gluco-
toxicity; DeFronzo’s studies of phlorizen,
which reduces glucose levels by increas-
ing glycosuria, showed improvement in
-cell function. Increased amyloid
polypeptide(IAPP) deposition is another
factor leading to -cell failure, with rela-
tive islet amyloid area increased in associ-
ationwithdecreasedinsulinsecretionand
increased fasting glucose in a nonhuman
primate study.
DeFronzo discussed insulin resis-
tance in type 2 diabetes, noting potential
differences between the fasting and insu-
lin-stimulated states. In type 2 diabetic
patients, elevation in basal hepatic glu-
cose production correlates strongly with
increase in fasting glucose, while in the
insulin-stimulated state the insulin resis-
tance of type 2 diabetes is largely ac-
counted for by skeletal muscle insulin
resistance. Intramyocellular defects in-
clude impaired glucose transport and de-
creasedglycogensynthesis.Insulinaction
begins with insulin receptor auto-
phosphorylation,thencausingphosphor-
ylation of insulin receptor substrate
(IRS)-1, leading to activation of a number
of intracellular processes, with a decrease
in the ability of the insulin receptor to
tyrosine phosphorylate IRS-1 in insulin
resistance. At the same time, the mito-
genic insulin response pathway is rela-





DeFronzo showed fascinating differ-
ences between the effects of oral and par-
enteral glucose. The latter only increases
hepatic glucose uptake when plasma glu-
cose levels increase, even during hyperin-
sulinemia. Oral glucose, in contrast,
markedly increases hepatic glucose up-
take in normal individuals, acting to a
lesser extent in type 2 diabetic patients,
which suggests an abnormality of a gut
factor. Increased FFAs may play a role in
inhibiting muscle glucose uptake, in-
creasing hepatic glucose production, and
decreasing insulin secretion. The use of
lipid plus heparin infusion to elevate FFA
innormalindividualsdecreaseshepaticand
muscleinsulinsignalingviaanumberofty-
rosine phosphorylation steps and results in
a doubling of muscle lipid content. Piogli-
taozne increases the expression of perox-
isome proliferators–activated receptor
(PPAR)- coactivator (PGC)-1, thereby
reducing intramyocellular lipid and fatty
acylCoA content, an effect similar to that
with administration of the nicotinic acid
derivative acipimox to reduce circulating
FFAs. Decreased incretin effect is another
factor in the pathogenesis of type 2 diabe-
tes. A 2-week course of exenatide in type
2 diabetic patients showed beneﬁcial ef-
fects, inlcuding an improved ratio of in-
sulin secretion to 2-h glucose and
increased splanchnic glucose uptake. Ab-
normalities of -cell function may be an-
other factor in the pathogenesis of type 2
diabetes. Marking another beneﬁt of in-
cretintreatmentapproaches,glucagonse-
cretion is increased and correlates with
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further improves after administration of
somatostatin. In addition, there are cen-
tral nervous system effects on glycemia,
and the hyperinsulinemia of obesity may
involve central insulin resistance, with
evidence of altered hypothalamic func-
tion in obese individuals after glucose
ingestion.
Given the variety of pathogenic
abnormalities in type 2 diabetes, its treat-
mentrequiresmultipledrugsincombina-
tion.MetforminandTZDsactontheliver,
and TZDs act on muscle, the adipocyte,
and the -cell, suggesting to DeFronzo
that these agents are preferable to met-
formin and to sulfonylureas. All long-
term TZD studies, he said, including
PERISCOPE, CHICAGO, ADOPT, and
the UKPDS, show that sulfonylureas do
not give durable glycemic beneﬁt, while
long-termglucose-loweringisseenwith
TZDs in type 2 diabetic patients and in
prevention studies such as the DPP, TRI-
POD, PIPOD, DREAM, and ACT-NOW.
“The TZDs and the GLP-1 analogs,” De-
Fronzoconcluded,“offeranewtherapeu-
tic approach.” This is, he said, preferable
to the stepwise approach of typically us-
ing metformin followed a sulfonylurea
recommended by ADA, which he charac-
terized as “nonphysiological.” He recom-
mended a “pathophysiologic-based
algorithm” of initial treatment with life-
style, TZDs, metformin, and exenatide,
with an A1C goal 6%, suggesting that
this would be durable, would result in
-cell preservation, and would not cause
hypoglycemia or weight gain.
These and many additional ap-
proaches to treatment of type 2 diabetes
were explored in studies presented at the
ADA meeting.
Metformin
Foretz et al. (abstract 1507) investigated
the relationship between metformin’s ac-
tivation of AMP-activated protein kinase
(AMPK) and its inhibition of gluconeo-
genesis, ﬁnding that although hepato-
cytes from mice not expressing AMPK
had a 30% reduction in gluconeogenesis,
both in the basal state and in response to
cyclic AMP, metformin reduced glucose
production to a greater extent in the
knockout hepatocytes than in those from
wild-type animals. Mice overexpressing
PGC-1, which is distal to AMPK in acti-
vation of gluconeogenesis, continued to
respondtometformin.Theauthorsfound
that metformin reduced intracellular
ATP, suggesting that this rather than its
effectonAMPKmightexplainitseffecton
gluconeogenesis. (Abstract numbers refer
to the ADA Scientiﬁc Sessions, Diabetes
57 [Suppl. 2], 2008).
This work was supported by Baverel
et al. (abstract 38), who found a dose-
dependent inhibition by metformin of
gluconeogenesis from lactate in liver
slicesfromZuckerdiabeticfattyratsanda
reduction of cellular ATP levels and of
CO2 production from lactate, while lac-
tate production and ketogenesis nearly
doubled with increased -hydroxybu-
tyrate–acetoacetate ratio, reﬂecting the
mitochondrial redox state. Schaefer et al.
(abstract97)treated19nondiabeticobese
adults with 850 mg metformin daily for
one week, then twice daily for three more
weeks, showing a reduction in 24-h en-
ergy expenditure by 3% with carbohy-
drate and fat oxidation increasing 17%
and decreasing 33%, respectively.
A number of other agents may regulate
pathways similar to those affected by met-
formin. Van Poelje et al. (abstract 350)
found a reduction in glucose production
from lactate in human hepatocytes with
the fructose-1,6-bisphosphatase inhibitor
MB07803. In diabetic rodents and nonhu-
man primates, glucose decreased without
any change in blood lactate. Motoshima et
al. (abstract 351) found that the protein
kinase C inhibitor rottlerin decreased
AMPK phosphorylation in adipocytes,
myocytes, and hepatocytes and increased
cellular glucose consumption; the latter
effectisnotobservedwithoverexpression
of dominant-negative AMPK, which sug-
gests this phenomenon to mediate the
glucose-lowering effect observed in ani-
mal models in vivo.
PPAR agonists
A number of studies at the ADA meeting
contributed to the endeavor to unravel
cardiovascular (CV) risks versus beneﬁts
of the TZDs. Bilik et al. (abstract 300)
compared 8,739 type 2 diabetic patients
who were followed from 1999 to 2003
and either received or did not receive a
TZD. Mortality among the patients was 5
vs. 7%, and major CV events occurred in
11 vs. 10%, respectively. A total of 817
took just rosiglitazone and 724 just pio-
glitazone, with major CV events in 9 and
10%, respectively. However, Wang et al.
(abstracts 590 and 604) analyzed 11,283
type 2 diabetic patients receiving either
metformin or a sulfonylurea alone at
baseline. They found a 23% greater like-
lihood of a CV event among patients re-
ceiving add-on rosiglitazone than among
those receiving combined sulfonylurea-
metformin treatment. Spanheimer et al.
(abstract 299) reported that 33% of pa-
tients in the PROspective pioglitAzone
Clinical Trial In macroVascular Events
(PROactive) were treated with insulin,
39% with a nitrate, and 70% with an
angiotensin-directed agent, with no evi-
dence of these treatments increasing risk
of stroke, myocardial infarction, or mor-
tality. Seung Jin Han et al. (abstract 435)
administered pioglitazone versus placebo
to 75 nondiabetic renal allograft recipi-
ents for 12 months, and found a signiﬁ-
cant increase versus decrease in insulin
sensitivity and a decrease versus increase
in carotid intima-media thickness. Bao
et al. (abstract 441) studied outcome
among 3,713 diabetic patients treated
with metformin alone for at least 12
months; 29 and 71% of the patients sub-
sequently took rosiglitazone and a sulfo-
nylurea, respectively. On average, the
latter group was 2 years older; the patient
groups had a similar sex distribution and
prevalenceofhypertensionandCVD,and
baseline resource utilization was similar.
Comparing those adding rosiglitazone
versus sulfonylurea, 74 vs. 69% were ad-
herent to glucose-lowering therapy, 23
vs. 27% experienced hospitalizations, 26
vs. 29% had ER visits, and 54 vs. 58% had
outpatient visits. There was a 40% greater
adjusted likelihood of adherence to rosigli-
tazone, and rates of both hospitalizations
and ER visits were 20% lower among those
who added rosiglitazone.
Tintetal.(abstract303)administered
rosiglitazone for 16 weeks to 14 type 2 dia-
betic patients of Chinese and Asian Indian
ethnicity. Euglycemic-hyperinsulinemic
clamp insulin sensitivity increased 52 vs.
120%, respectively, with somewhat more
weight gain in those of Asian Indian eth-
nicity. Kritchevsky et al. (abstract 1736)
administered 30 mg pioglitazone daily
versus placebo to 88 nondiabetic adults
who had a BMI 27 kg/m
2 and were on a
calorie-restricted diet for 4 months;
weightlossdidnotdifferbetweenthepio-
glitazone and placebo groups, but men
receiving pioglitazone had 3% reduction
in percent body fat, while there was a 2%
reduction in the placebo group; there was
a greater reduction in visceral fat among
pioglitazone-treated men.
Chouetal.(abstract304)compareda
new TZD, rivoglitazone, at 1, 2, and 3 mg
doses, with pioglitazone 45 mg daily and
with placebo in a study of 441 type 2 di-
abetic patients. A1C decreased by 0, 0.4,
0.5, and 0% and increased 0.6%, re-
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15, and 21% with the 1, 2, and 3 mg
doses and 8% with pioglitazone, while
HDL cholesterol increased 11, 10, 14,
and 8%, respectively. Peripheral edema,
however, occurred in 14, 17, 24, and
11%, respectively, and weight gain was
alsomorelikelytooccuratthe2and3mg
doses. Truitt et al. (abstract 437) studied
426 patients receiving 0.5, 2, and 5 mg
rivoglitazone, 30 mg pioglitazone, and
placebo. The 2 and 5 mg doses had more
potent glycemic effects than pioglitazone,
althoughedemaoccurredin6and16%of
those receiving the 2 and 5 mg doses but
in only 0–1% of those receiving pioglita-
zone. There was also greater weight gain
with the higher rivoglitazone doses. An
interesting implication is that activation
of PPAR is submaximal with existing
TZDs at recommended dosages, with ad-
ditional glucose lowering possible, al-
though the greater risks of ﬂuid retention
and weight gain may make the more po-
tent agents not clinically viable.
Dunn et al. (abstract 499) adminis-
tered the non-TZD partial PPAR agonist
INT131 to 69 type 2 diabetic patients not
receiving a glucose-lowering agent. Fast-
ing glucose increased from 165 by 8
mg/dl with placebo and decreased from
163 and from 184 by 22 and 46 mg/dl
with 1 mg and 10 mg doses, respectively.
Guha et al. (abstract 1478) studied the
effect of the PPAR agonist KD3010,
which exhibits 1,000-fold selectivity
over human PPAR and - and has been
associated with weight loss, in diabetic
db/db mice. A1C, fasting insulin, and
postload glycemia decreased. Multani et
al. (abstract 569) administered this agent
to normal and obese volunteers, improv-
ing peripheral insulin resistance and re-
ducing fasting insulin levels; no weight
gain or signs of ﬂuid retention or other tox-
icity were exhibited. Marita (abstract 196)
studied a non-TZD, P1736-05, that does
not activate human PPAR or - receptors
butincreasesadipocyteglucoseuptakeviaa
process involving phosphatidylinositol-3
kinase and thereby induces translocation of
GLUT4 transporter to the plasma mem-
brane. In a type 2 diabetic model, this pro-
cess reduces glucose and triglyceride levels
and improves muscle insulin-induced glu-
cose uptake without increasing plasma vol-
ume at 60-fold the effective dose.
Bile acid sequestrants in type 2
diabetes
Schwartzetal.(abstract440)randomized
35 type 2 diabetic patients to 3.75 g
colesevelam daily versus placebo for 8
weeks, ﬁnding no effect on the glucose
responsetoastandardizedmealtolerance
test. This ﬁnding suggests the effect of the
agent is not mediated by altered glucose
absorption. Jialal et al. (abstract 459) an-
alyzed the pooled effect of the bile acid
binding resin colesevelam in 1,081 type 2
diabetic patients receiving insulin, met-
formin, or a sulfonylurea, and found a
0.5%placebo-adjustedreductioninA1C,
a 15 mg/dl reduction in fasting glucose,
and a 15% reduction in LDL cholesterol
but a 7% reduction in non-HDL choles-
terol, reﬂecting a 15% increase in triglyc-
eride levels. Guha et al. (abstract 439)
administered an agonist of the gut bile
acid receptor TGR5 in type 2 diabetic an-
imal models, showing an improvement in
glycemia and insulin sensitivity and in-
creased active GLP-1 levels in portal and
systemic circulation. Brufau et al. (ab-
stract 1553) reported the cholic acid syn-
thesis rate to be increased by 70% in type
2 diabetic patients, with a consequent in-
crease in deoxycholic acid synthesis, pool
size, and total bile acid synthesis. As bile
acids are ligands for nuclear FXR and cell
membrane TGR5 receptors, this may be
related to abnormal glycemia in diabetes




The kidney ﬁlters 160 g glucose daily,
with 90% reabsorbed by sodium-glucose
cotransporter 2 (SGLT2) and 10% by
SGLT1 in the renal tubules. Interestingly,
in animal models of diabetes and in dia-
betic patients, the maximal renal tubular
reabsorptive capacity is increased.
Wancewicz et al. (abstract 334) adminis-
tered ISIS 388626, an SGLT2 antisense
oligonucleotide designed to speciﬁcally
distribute to the kidney, in canine and ro-
dent diabetic models. Administration of
ISIS388626resultedinimprovedglucose
levels and may be an effective treatment
modality. List et al. (abstracts 329 and
461)administered2.5–50mgoftherenal
SGLT2 inhibitor dapagliﬂozin daily,
1,500 mg metformin daily, or placebo to
389 treatment-naïve type 2 diabetic pa-
tients for 12 weeks, and found dose-
related 52–85 g/day glycosuria with
dapagliﬂozin. There was no change in se-
rum sodium, potassium, or creatinine or
in serum or urinary calcium. Magnesium
increased 0.1–0.2 mEq/l, urate decreased
1 mg/dl, and serum phosphate increased
0.2 mg/dl at the highest doses. At base-
line, A1C was7.7–8% and decreased by
0.7–0.9% with dapagliﬂozin, 0.7% with
metformin, and 0.2% with placebo, and
there were 2.7–3.4, 1.7, and 1.2% weight
losses, respectively. Adverse events with
dapagliﬂozin included urinary tract infec-
tion, nausea, dizziness, headache, fatigue,
back pain, and nasopharyngitis.
Chaudhury et al. (abstract 729), however,
in an effort to address the question of
whether glycosuria is associated with renal
tubular damage in 106 newly diagnosed
untreated type 2 diabetic individuals,
showedthedegreeofglycosuriatocorrelate
with a marker of proximal tubular damage.
A1C was an independent predictor, raising
the question of whether a therapeutic ap-
proach to increasing glycosuria might have
adverse renal effects.
G protein–coupled receptor
Fyfe et al. (abstract 297) studied PSN821,
an agonist of G protein–coupled receptor
(GPR)119expressedinpancreasandgut,
and showed stimulation of both -cell in-
sulinandgutGLP-1secretioninvitroand
improved glucose tolerance in type 2 pre-
diabeticanddiabeticanimalmodels.A1C
was lower in the latter, and weight was
reducedinadietaryobesitymodel.Trem-
blay et al. (abstract 1489) evaluated mice
not expressing GPR-39, which is nor-
mally expressed in the gastrointestinal
tract, adipose tissue, liver, and pancreatic
islets. The researchers found reduced se-
rum insulin and elevated glucose levels
associated with a high-fat diet or aging,
which suggests that agonists of GPR-39
might have glucose-lowering effects.
Zhou et al. (abstract 541) studied activa-
tors of GPR-40 (which is expressed in
pancreatic -cells) and found enhanced
glucose-dependent insulin secretion in
vitro and improved glucose tolerance in
type 2 diabetic models.
Glucokinase activators
Glucokinase (GK) has glucose afﬁnity in
the physiologic range of 5–12 mmol/l/l,
allowingittofunctionasaglucosesensor.
The diabetes variant MODY2 is caused by
decreased hepatic GK activity, while acti-
vating GK mutations cause hyperinsu-
linemic hypoglycemia of infancy. GK acts
inthe-celltoformglucose-6-phosphate
andincreaseintracellularATP,closingthe
ATP-sensitive potassium channel, depo-
larizing the cell, and opening a calcium
channel, thereby leading to insulin secre-
tion. As such, there has been interest in
GK activators as insulin secretagogues. In
the liver, GK is the rate-limiting step for
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cogen formation, so that GK activators
could also increase hepatic insulin action.
Archer et al. (abstract 465) studied the
small molecule GK activator ARRY-588,
which is capable of increasing glucose-
induced -cell insulin secretion as well as
that of GIP and GLP-1, and of reducing
glucose levels in type 2 diabetic models,
without hyperinsulinemia or weight gain.
Inadditiontotheliver,the-cell,andgut
L- and K-cells, GK is expressed in -cells
and in hypothalamic neurons involved in
physiologic glucose-sensing. Nakamura
et al. (abstract 493) showed that a small
molecule GK activator increased glucose-
stimulated insulin secretion in islets from
mice with and without -cell–speciﬁc
haploinsufﬁciency of the GK gene. In
high-fat-fed mice, glucose tolerance im-
proved with the agent, again with and
without deletion of one copy of the GK
gene. Bodvarsdottir et al. (abstract 328)
studied the liver-speciﬁc GK activator
TTP355, showing increases in vitro in he-
patocyte glucose metabolism, without ef-
fect on insulin secretion, and showing
improvement in glycemia in a type 2 dia-
beticanimalmodel.Bonadonnaetal.(ab-
stract 322) reported improved glucose
levels and increased insulin secretion in
15 mild type 2 diabetic patients receiving
another GK activator, RO4389620.
Dipeptidyl peptidase-4 inhibitor
treatment
Hjollund et al. (abstract 1464) measured
portal vein active GLP-1 levels in pigs,
ﬁnding an increase from 6.6 to 45.1
pmol/l after administration of bombesin
(neuromedin C). After dipeptidyl pepti-
dase-4 (DPP-4) inhibition with vildaglip-
tin, GLP-1 increased from 16.3 to 90.3
pmol/l. Portal levels were two to three
timesgreaterthanperipheralbloodlevels,
potentially acting on the liver and on va-
gal afferents, which the authors suggest
might explain the comparable glycemic
effect of DPP-4 inhibitors to those of
GLP-1 receptor activators. Peripheral
blood GLP-1 receptor activation appears
to be much lower with DPP-4 inhibition,
butportallevelsmaybecomparable.Aul-
inger et al. (abstracts 1,545 and 1,551)
reported that although neither GLP-1 nor
vildagliptin reduced food intake given
separately in a rat feeding model, com-
bined administration was effective. Ex-
enatide showed a more potent and
longer-lasting anorexic effect and, inter-
estingly, the combination of exenatide
with vildagliptin suppressed food intake
to an even greater extent, suggesting a
potential clinical beneﬁt of combined
treatmentofoverweightpatientswithdi-
abetes. Two interesting studies suggest
that some of the effects of -glucosidase
inhibitionmaybemediatedbychangesin
incretin secretion. Narita et al. (abstract
447)reportedeffectsofmiglitolonGLP-1
andGIPresponsestoamixedmealinnine
type 2 diabetic patients, ﬁnding a modest
increase in GLP-1 concentrations by ap-
proximatelyone-thirdat60and120min,
but a marked reduction in GIP by 60% at
30 and 60 min, with a 3-h integrated in-
creaseinGLP-1anddecreaseinGIPby14
and 47%, respectively. Goto et al. (ab-
stract 470) administered miglitol and the
DPP-4 inhibitor SK-0403 in combination
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes
treatment will be highlighted in this section.
AninterviewwithDr.DavidOrloff,formerdirectorofthedivisionofmetabolism
andendocrinologyproductsattheFDA,reviewedtherecentFDAcardiovascular
risk assessment guidelines for diabetes drugs, pointing out that the guidelines
would increase the cost and time of developing a diabetes drug and suggesting
that several companies are likely to discontinue development of their diabetes
drugs (interview downloaded January 26, 2009, from http://www.close
concerns.com/). To understand this, it may be useful to review the guidelines,
which state, “For completed studies, before submission of the new drug appli-
cation (NDA)/biologics license application (BLA), sponsors should compare the
incidence of important cardiovascular events occurring with the investigational
agent to the incidence of the same types of events occurring with the control
group to show that the upper bound of the two-sided 95 percent conﬁdence
interval for the estimated risk ratio is less than 1.8” (http://www.fda.gov/cder/
guidance/8576fnl.pdf).
Consider drugs that are completely neutral with regard to cardiovascular out-
come.SaythatdrugAfromcompanyAistestedinapopulationof2,000patients,
with2,000controlsubjects,inwhomthecardiovasculareventrateis1%.Ifboth
groups have precisely 20 cardiovascular events, the relative risk (RR) ratio is, of
course,1.0.The95%CI,however,wouldbe0.5397-1.8528.Now,saycompany
B performed the same studies, but in their case there were 20 events among the
2,000 patients receiving drug B but 21 events among the 2,000 control subjects.
The relative risk is now 0.95, with a 95% CI of 0.5179-1.7514 (CIs for RRs and
odds ratios calculated with a statistical calculator downloaded 25 January 2009
from vl.academicdirect.org/applied_statistics/binomial_distribution/ref/CI
calculator.xls, according to the methods described in the following source: Ar-
mitage P, Berry G: Statistical Methods in Medical Research. 3rd ed. London, Black-
well, 1994, p. 131). Certainly, drug A and drug B have indistinguishable
cardiovascular risk. Yet, the language of the FDA document states clearly that
company A, but not company B, will need to undertake a postmarketing trial “to
deﬁnitively show that the upper bound of the two-sided 95 percent conﬁdence
interval for the estimated risk ratio is less than 1.3.” Company A now needs to
study a total of 12,000 patients in each group to show that, with 1% cardiovas-
cular event rates, the same RR of 1.0 has a 95% CI of 0.7774-1.2863. It appears,
then,thatarbitraryandstatisticallymeaninglessdifferencesmayleadsomecom-
panies to abandon the development of potentially promising new therapies for
diabetes—certainly an undesirable and hopefully an unintended result of the
FDA guidance.
The FDA issued a Public Health Advisory to alert consumers, patients, health
care professionals, and caregivers about potentially serious and life-threatening




arrhythmia, seizures, respiratory difﬁculty, or decreased mental status.
Perspectives on the News
e28 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009in a rat model, showing that after a mixed
meal the combination increased GLP-1
levels to a greater extent than the DPP-4
inhibitor alone. Miglitol alone did not
change GLP-1 levels, and curiously the
GLP-1 response to oral sucrose was less
with the combination than with SK-0403
alone. As in the human study, GIP levels
after the mixed meal were reduced by ad-
ministration of miglitol.
Williams-Herman et al. (abstract
495) and Katzeff et al. (abstract 496)
found, adjusting for baseline A1C, a
greater placebo-controlled reduction in
A1C by use of sitagliptin among individ-
uals in the highest proinsulin/insulin ter-
tile and in the lowest HOMA- tertile in
four randomized controlled trials of
1,691 type 2 diabetic patients. Lower
-cell function may be associated with
greater response to sitagliptin. There was
no differential effect by age, sex, or BMI
group.Chapelletal.(abstract512;disclo-
sure: ZB was a coauthor) compared the
glucose-lowering effects of sitagliptin,
pioglitazone, and rosiglitazone in a meta-
regressionanalysisof23randomizedcon-
trolled studies, ﬁnding weighted mean
reduction in A1C of 0.7, 0.9, and 0.5%,
respectively. Differences in baseline A1C
explained most of the apparent difference
between the agents, with strong correla-
tion between baseline A1C and change in
A1C across studies.
TwonewDPP-4inhibitorsareunder-
going clinical testing. Rosenstock et al.
(abstract517)administeredtheDPP-4in-
hibitor saxagliptin (2.5, 5 and 10 mg
daily) to 401 drug-naïve type 2 diabetic
patients for 24 weeks. The researchers
found a placebo-adjusted reduction in
fasting glucose of 21, 15, and 23 mg/dl
and in A1C of 0.6, 0.6, and 0.7%, respec-
tively.Adverseeventsoccurringinatleast
5% of patients included respiratory infec-
tion, headache, nasopharyngitis, and si-
nusitis, presumably an overlapping
complex of diagnoses, and urinary infec-
tion. Karim et al. (abstract 538) adminis-
tered the DPP-4 inhibitor alogliptin (50
mg) to six individuals with a creatinine
clearance of 51–80 ml/min, six individu-
als with a creatinine clearance of 30–50
ml/min, six individuals with a creatinine
clearance of 30 ml/min (but not on di-
alysis), and six individuals with end-stage
renalinsufﬁciency.Theresearchersfound
a 1.7-, 2.1-, 3.2-, and 3.8-fold increased
plasma exposure over 5 days when com-
pared with six healthy individuals with
normal renal function. The authors sug-
gested that the dose should be reduced to
one-halfandone-quarterwithglomerular
ﬁltration rates 50 and 30 ml/min, re-
spectively,althoughthereisapresumable
overlap between the 1.7- and 2.1-fold in-
creases; therefore, the dose might also be
reduced in the 51–80 ml/min group.
Fleck et al. (abstract 479) administered
alogliptin 6.25, 12.5, 25, 50, or 100 mg
daily or placebo for 12 weeks to 265 type
2 diabetic patients not receiving pharma-
cologic treatment. The researchers found
lacebo-adjusted A1C reductions of 0.2,
0.5,0.6,0.4,and0.5%,respectively,from
baseline levels of 8–8.2%. Pratley et al.
(abstract478)addedalogliptin12.5or25
mg or placebo for 26 weeks in 493 type 2
diabetic patients receiving pioglitazone;
some of the patients were also receiving
metformin or a sulfonylurea. A1C de-
creased 0.7% and 0.8% with 12.5 and 25
mg alogliptin and 0.2% with placebo, ex-
hibiting a greater reduction with a higher
baseline A1C level. Nauck et al. (abstract
477) administered alogliptin 12.5 or 25
mg or placebo for 26 weeks in 527 type 2
diabetic patients receiving metformin,
ﬁnding 0.6%, 0.6%, and 0.1% reduction
in A1C and 19, 17, and 0 mg/dl falls in
fasting glucose. DeFronzo et al. (abstract
446) administered alogliptin 12.5 or 25
mg or placebo for 26 weeks to 329 type 2
diabetic patients not receiving pharmaco-
logic treatment, ﬁnding 0.6%, 0.6%, and
no reduction in A1C and a 10 and 16
mg/dlreductionandan11mg/dlincrease
in fasting glucose, respectively. Pratley et
al. (abstract 445) added 12.5 or 25 mg
alogliptin or placebo for 26 weeks to 500
type 2 diabetic patients receiving gly-
buride, ﬁnding 0.4%, 0.5%, and no re-
duction in A1C with 5 and 8 mg/dl
decreasesanda2mg/dlincreaseinfasting
glucose, respectively. Rosenstock et al.
(abstract 444) added 12.5 or 25 mg alo-
gliptin or placebo for 26 weeks to 390
type 2 diabetic patients receiving insulin,
alone or with metformin, with 0.6%,
0.7%, and 0.1% reductions in A1C and a
2 mg/dl increase, a 12 mg/dl decrease,




Brian Kennedy (Merck Frosst Centre for
Therapeutic Research, Pointe-Claire-
Dorval, PQ, Canada) discussed protein
tyrosine phosphatase (PTP)-1B, insulin
sensitivity,andweightcontrol.Insulinre-
ceptor (IR) signal transduction involves
its autophosphorylation. PTP dephos-
phorylates the IR, returning it to the inac-
tive state, with inhibition of IR-PTP
prolonging the insulin signal. Mice not
expressing this enzyme display remark-
able tissue speciﬁcity of insulin sensitiv-
ity, with a reduction in fed blood glucose,
a 50% lowering of insulin levels, and in-
creased tyrosine phosphorylation of the
IR in muscle and liver, without effect in
adipose tissue, leading to resistance to di-
et-induced obesity (2). Hormone signal-
ing in adipocytes involves both insulin
and -adrenergic pathways. Insulin leads
tophosphodiesterase3bphosphorylation
and increases GLUT4 translocation to the
cell surface, while in the absence of insu-
lin, cAMP levels increase thereby leading
to activation of protein kinase A (PKA); in
mice not expressing PTP-1B, PKA activity
isincreasedinwhiteandbrownfatandin
muscle but not in liver, but there is adi-
pocyte insulin resistance, suggesting that
in adipocyte PTP-1B is a positive regula-
tor of insulin signaling. IR substrate
(IRS)-1 levels are reduced 40% in mice
not expressing PTP-1B, and IRS-1 phos-
phorylation is decreased, appearing to in-
volve the mTOR pathway. A number of
small-molecule PTP-1B inhibitors are be-
ing studied, with evidence of improved
glycemiainavarietyofobeserodentmod-
els. Interestingly, PTP-1B is overex-
pressed in breast cancer, and reduced
carcinogenesis has been shown in some
animal models with PTP-1B inhibitors.
Further therapeutic approaches
Santilli et al. (abstract 395) administered
100 mg acarbose three times daily versus
placebofor20weeksto48type2diabetic
patients with A1C 7%, ﬁnding fasting
and2-hpost-testmealglucosetodecrease
from 126 to 117 mg/dl and from 171 to
139mg/dl,respectively,withafallinA1C
from 6.7 to 6.3%. Urinary 11-dehydro-
thromboxane-B2 and 8-iso-prostaglan-
din-F2a, markers of platelet activation
and oxidant stress, decreased 40 and
30%, respectively, and correlated with
the reduction in postprandial rather than
in fasting glucose, potential cardioprotec-
tive effects. Hawkins et al. (abstract 344)
administeredINCB013739,aselectivein-
hibitor of 11-hydroxysteroid dehydro-
genase type 1, to 30 type 2 diabetic




eral glucose uptake. Fasting glucose
decreased 18 mg/dl and LDL cholesterol
20 mg/dl. Plasma ACTH increased 12 pg/
ml,althoughmorningplasmacortisollev-
Bloomgarden
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(abstract 508) studied Gynostemma pen-
taphyllum, also called jiaogulan or south-
ern ginseng tea, a traditional Vietnamese
herbal treatment. The researchers admin-
istered 6 g Gynostemma pentaphyllum
twice daily to 24 type 2 diabetic patients,
with a placebo-adjusted 43 mg/dl reduc-
tion in fasting glucose (baseline 180 mg/
dl) and a 1.8% reduction in A1C, with
evidence of improvement in insulin sen-
sitivity. Luo et al. (abstract 333) noted
that mice not expressing thyrotropin-
releasing hormone (TRH) are hyperglyce-
mic, and thyroxin does not improve this
effect.Inastreptozotocin-diabeticmodel,
TRH administration markedly reduced
the degree of hyperglycemia and main-
tained normal insulin levels. Normal ani-
mals receiving TRH alone had mild
hyperinsulinemia without hypoglycemia.
Several treatment approaches may
combine glycemic with cardiovascular
beneﬁt. Scranton et al. (abstract 331) ad-
ministered a rapidly absorbed formula-
tion of bromocryptine to increase early
morning dopaminergic activity versus pla-
cebo for 52 weeks to 3,070 type 2 diabetic
patients in the Cycloset Safety Trial (Clini-
calTrials.gov Identiﬁer NCT00377676),
showing a 42% reduction in the combina-
tion of myocardial infarction, stroke, coro-
nary revascularization, and hospitalization
foranginaorcongestiveheartfailure(P
0.036) and a 55% reduction in the com-
bination of myocardial infarction, stroke,
or death, with beneﬁt seen in subgroups
stratiﬁed by A1C (7 vs. 7%), age, sex,
or race. Chisholm et al. (abstract 528)
randomized 727 type 2 diabetic patients
to the anti-angina agent ranolazine versus
placebo, and found an A1C reduction
with active treatment which correlated
with baseline glucose; there was no rela-
tionship between glucose and change in
A1Cinthosereceivingplacebo.Klugetal.
(abstract 443) and Tardif (abstract 335)
treated 6,144 patients with acute coro-
nary syndrome with succinobucol, with a
19% decrease in the prespeciﬁed second-
aryendpointofcardiovasculardeath,car-
diac arrest, myocardial infarction, and
stroke. Of the 2,271 type 2 diabetic pa-
tients, 1,952 had evaluated A1C data,
showing a reduction from 7.2% by 0.5%,
without an increase in weight, waist cir-
cumference, or edema. Of those not hav-
ing diabetes, 82 of 1,950 who received
placebo versus 30 of 1,923 who received
succinobucol developed diabetes during
the period of observation. There was a
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